TRACON Pharmaceuticals, Inc. [TCON] saw a change by 6.84% with the Thursday trading session, closing the trade at the price of $0.81. The company is holding 30.47M shares with keeping floating shares. With the latest trading session, the stock is set at 62.40% off compared to its 52-week low, sliding -71.00% from high for the same period of time.
Since its 90-day high, the share price saw a move by -52.89%, trading +48.18% in oppose to its 90-day low While during the day, 30.47M shares valued at 1.22 million were bought and sold.
TRACON Pharmaceuticals, Inc. [NASDAQ:TCON]: Analyst Rating and Earnings
Expert stock traders often make certain they pay attention what leading Wall Street analysts think regarding a potential stock purchase. As it relates to TRACON Pharmaceuticals, Inc. [TCON] currently, the latest ratings from Wall St. experts that can be seen publicly is related to the fiscal quarter that’s scheduled to end in December. On average, stock market experts give TCON an Outperform rating. Its stock price has been found in the range of 0.50 to 2.80. This is compared to its latest closing price of $0.76.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for TRACON Pharmaceuticals, Inc. [TCON] is sitting at 2.33. This is compared to 1 month ago, when its average rating was 2.33.
Pay attention to the next-scheduled financial results for this company to be released, which is slated for Wed 14 Aug (In 49 Days).
Fundamental Analysis of TRACON Pharmaceuticals, Inc. [TCON]
Now let’s turn to look at profitability: with a current Operating Margin for TRACON Pharmaceuticals, Inc. [TCON] sitting at -1158.00.
This company’s Return on Total Capital is -132.86, and its Return on Invested Capital has reached -125.00%. Its Return on Equity is -181.94, and its Return on Assets is -91.07. These metrics suggest that this TRACON Pharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, TRACON Pharmaceuticals, Inc. [TCON] has generated a Total Debt to Total Equity ratio of 29.97. Similarly, its Total Debt to Total Capital is 23.06, while its Total Debt to Total Assets stands at 15.81. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 24.92, and its Long-Term Debt to Total Capital is 19.17. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.
What about valuation? This company’s Enterprise Value to EBITDA is 0.39. Total Debt to Enterprise Value stands at -0.41. TRACON Pharmaceuticals, Inc. [TCON] has a Price to Book Ratio of 0.88.
Shifting the focus to workforce efficiency, TRACON Pharmaceuticals, Inc. [TCON] earns $115,385 for each employee under its payroll. Similarly, this company’s Total Asset Turnover is 0.08. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 3.01 and its Current Ratio is 3.01. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
TRACON Pharmaceuticals, Inc. [TCON] has 30.47M shares outstanding, amounting to a total market cap of $23.16M. Its stock price has been found in the range of 0.50 to 2.80. At its current price, it has moved down by -71.00% from its 52-week high, and it has moved up 62.40% from its 52-week low.
This stock’s Relative Strength Index (RSI) is at 70.57. This RSI suggests that TRACON Pharmaceuticals, Inc. is currently Overbought.
Conclusion: Is TRACON Pharmaceuticals, Inc. [TCON] a Reliable Buy?
TRACON Pharmaceuticals, Inc. [TCON] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.